Effect of galantamine on smoking abstinence
Brief Description Of Study
Nicotine dependence is a major public health problem and currently available treatments are ineffective for the majority of smokers. Thus, there is an urgent need to develop and test new medications to aid in smoking cessation. Recent evidence from a genetic study of prospective smoking cessation conducted at the CIRNA suggests that smoking cessation may be influenced by variation in acetylcholine levels. The proposed proof-of-concept study is a randomized, double-blind placebo-controlled, parallel arm pilot study of the effects of the acetylcholinesterase inhibitor, galantamine (vs. placebo), on short-term abstinence among 80 treatment-seeking smokers. The primary outcome is the number of days abstinent during a 7-day quit attempt. Secondary outcomes include: smoking rate during the run-up and monitored abstinence phase, medication adherence, side effects, cognition, and smoking urges and other withdrawal symptoms. The data generated will be used to support an NIH grant application by a new investigator to evaluate whether acetylcholinesterase inhibitors could be effective smoking cessation medications.